Genmab Statistics

Total Valuation

Genmab has a market cap or net worth of DKK 82.07 billion. The enterprise value is 78.99 billion.

Market Cap	82.07B
Enterprise Value	78.99B

Important Dates

The last earnings date was Thursday, May 8, 2025.

Earnings Date	May 8, 2025
Ex-Dividend Date	n/a

Share Statistics

Genmab has 62.18 million shares outstanding. The number of shares has decreased by -2.27% in one year.

Current Share Class	62.18M
Shares Outstanding	62.18M
Shares Change (YoY)	-2.27%
Shares Change (QoQ)	-0.34%
Owned by Insiders (%)	1.11%
Owned by Institutions (%)	52.40%
Float	61.48M

Valuation Ratios

The trailing PE ratio is 10.81 and the forward PE ratio is 12.96. Genmab's PEG ratio is 4.21.

PE Ratio	10.81
Forward PE	12.96
PS Ratio	3.79
PB Ratio	15.50
P/TBV Ratio	25.77
P/FCF Ratio	10.74
P/OCF Ratio	10.47
PEG Ratio	4.21

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 10.44, with an EV/FCF ratio of 10.33.

EV / Earnings	10.07
EV / Sales	3.65
EV / EBITDA	10.44
EV / EBIT	11.05
EV / FCF	10.33

Financial Position

The company has a current ratio of 5.34, with a Debt / Equity ratio of 0.03.

Current Ratio	5.34
Quick Ratio	5.32
Debt / Equity	0.03
Debt / EBITDA	0.02
Debt / FCF	0.02
Interest Coverage	59.10

Financial Efficiency

Return on equity (ROE) is 41.53% and return on invested capital (ROIC) is 22.95%.

Return on Equity (ROE)	41.53%
Return on Assets (ROA)	20.66%
Return on Invested Capital (ROIC)	22.95%
Return on Capital Employed (ROCE)	122.66%
Revenue Per Employee	8.20M
Profits Per Employee	2.97M
Employee Count	2,682
Asset Turnover	1.00
Inventory Turnover	16.95

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -34.10% in the last 52 weeks. The beta is 0.90, so Genmab's price volatility has been similar to the market average.

Beta (5Y)	0.90
52-Week Price Change	-34.10%
50-Day Moving Average	1,379.50
200-Day Moving Average	1,556.92
Relative Strength Index (RSI)	45.75
Average Volume (20 Days)	200,217

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Genmab had revenue of DKK 21.64 billion and earned 7.85 billion in profits. Earnings per share was 122.05.

Revenue	21.64B
Gross Profit	20.64B
Operating Income	7.15B
Pretax Income	9.16B
Net Income	7.85B
EBITDA	7.46B
EBIT	7.15B
Earnings Per Share (EPS)	122.05

Full Income Statement

Balance Sheet

The company has 3.23 billion in cash and 143.00 million in debt, giving a net cash position of 3.08 billion or 49.58 per share.

Cash & Cash Equivalents	3.23B
Total Debt	143.00M
Net Cash	3.08B
Net Cash Per Share	49.58
Equity (Book Value)	5.30B
Book Value Per Share	83.61
Working Capital	3.28B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 7.84 billion and capital expenditures -195.00 million, giving a free cash flow of 7.64 billion.

Operating Cash Flow	7.84B
Capital Expenditures	-195.00M
Free Cash Flow	7.64B
FCF Per Share	122.94

Full Cash Flow Statement

Margins

Gross margin is 95.38%, with operating and profit margins of 33.05% and 36.26%.

Gross Margin	95.38%
Operating Margin	33.05%
Pretax Margin	42.33%
Profit Margin	36.26%
EBITDA Margin	34.49%
EBIT Margin	33.05%
FCF Margin	35.33%

Dividends & Yields

Genmab does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	2.27%
Shareholder Yield	2.27%
Earnings Yield	9.56%
FCF Yield	9.31%

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Genmab has an Altman Z-Score of 58.55.

Altman Z-Score	58.55
Piotroski F-Score	n/a